Background: Comprehensive cancer care uses complementary approaches alongside specific anticancer therapy. Using a dedicated questionnaire, the Calista2 survey sought to assess the importance of supportive care and activities among lung cancer (LC) patients, how often these services are made available and offered, the utilization rate, and the frequency of unmet needs. Method: The 25 physicians who accepted to take part in the survey recruited 198 patients of whom 143 answered the patient-reported questionnaire. Patients meeting the inclusion criteria were adults already on specific therapy for advanced LC. The patient-reported questionnaires covered drug management of pain, fatigue, adverse effects of treatments (AE), and sleep disorders, social and psychological support, physical activities, and complementary and alternative medicines. Items were rated on a 0 e 10 scale. Questionnaires were collected between September 2016 and October 2017. Result: After exclusion of non-valid patient questionnaires, 134 were analyzed. The mean age of these patients was 64.3 years (SD:8.5). There were 62% men and 37% women. Patients perceived the management of pain, AE and fatigue as the three most important items (7.5, 7.2, 6.0) while counselling with regards to employment (1.7), spiritual support (2.6), art therapy (2.6), and support groups for patients' children (2.6) were the least important. Although most of the facilities were available at the point of care, complementary medicines, art therapy, and professional counselling were accessible for 29%, 33%, and 21%, respectively. Physicians frequently suggested pain and AE management (78%, and 75%, respectively), and diet counselling (51%). In contrast, fatigue management, sleep disorders, and sexual issues were less frequently addressed (35%, 44%, and 6%, respectively). Paradoxically, the four main unmet needs were management of fatigue, complementary medicines, psychological support for the patient's family and friends and relaxation techniques (32%, 25%, 20%, and 20%, respectively). Conclusion: These key findings highlight the fact that support for pain and for the AE of cancer treatment are available, suggested and used. In contrast, unmet needs expressed by the patients were either available but not used (fatigue management and psychological support for the patient's family and friends) or rarely available (complementary medicines and relaxation techniques).
P2.15-18 Cost-Effectiveness Analysis of Second-Line Immune Checkpoint Inhibitors for Advanced NSCLC in Colombia
A.V. Ospina Serrano, 1 P. Aguiar Jr., 2 R. Bruges, 3 J. Gonzalez Diaz, 4 A. Del Giglio, 2 G. Lopes 5 1 Iccal Hospital Universitario Fundacion Santa Fe de Bogota, Bogota/CO, 2 Faculdade de Medicina Do Abc, Santo Andre/ BR, 3 Instituto Nacional de Cancerologia, Bogota/CO, 4 Oncologos Del Occidente, Armenia/CO, 5 Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL/US Background: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The greatest challenge in oncology today is how to reconcile improvements in the management of cancer with the exponentially increasing costs of new treatment and this is a very important barrier in low and middle income countries. The objective of this study was to assess the cost-effectiveness and economic impact of second-line treatment with nivolumab and pembrolizumab with and without the use of PD-L1 testing for patient selection in Colombia. Method: We designed a decision-analytic model to evaluate the cost-effectiveness of second-line immunotherapy versus docetaxel for advanced NSCLC. We considered the outcomes from randomized clinical trials (RCTs). Direct and indirect costs were retrieved with a colombian perspective. We followed standard recommendations for the conduct and reporting of health economic analyses. Primary endpoint were Incremental Cost Effectiveness Ratios (ICER), for treatment with nivolumab and pembrolizumab with and without PDL1 testing. Result: Nivolumab improved quality-adjusted life-years (QALY) by 0.417 among squamous tumors and 0.287 among non squamous tumors. The ICER were $135,093 COP and $179,391 COP, respectively. Pembrolizumab achieved a QALY gain of 0.346 and the ICER was $146,022 COP. The use of PD-L1 expression as a tailor biomarker for nivolumab among nonsquamous tumors improved incremental QALY by up to 157% and decreased the ICER by up to 61% compared with treating all patients. Considering a willingness to pay threshold of three times the Colombian Gross Domestic Product per capita, second-line immunotherapy was not cost-effective with or without patient selection by PD-L1 expression. Conclusion: Patient selection by PD-L1 expression increased cost-effectiveness of immunotherapy. Second-line immunotherapy was not cost-effective in Colombia due to its high cost. Taking into account the disparities in access to cancer innovative therapies, there is a need to promote strategies to reduce drug acquisition costs, such as price discrimination and the use of biosimilars or generics. Keywords: cost effectiveness, pharmacoeconomics, Inmunotherapy
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Inequality of Access to Novel Lung Cancer Therapies in Europe H. O'Sullivan L. Coate University Hospital Limerick, Limerick City/IE Background: With an estimated incidence of over 449,000 cases per year, lung cancer is one of the most common malignancies in Europe. Over the last decade the landscape of lung cancer treatment has evolved. We have entered a new era of lung cancer treatment and high costs has led to disparities in lung cancer care among different European countries. There is evidence of discrepancy in access to cancer therapies in Europe however access to contemporary targeted agents and immunotherapy for lung cancer hasn't been studied. We analysed the reimbursement dates of novel lung cancer therapies in Europe. Method: The lung cancer therapies investigated include the tyrosine kinase inhibitors (TKI) alectinib, ceritinib, and crizotinib. Immunotherapy agents nivolumab, pembrolizumab and atezolizumab were also researched. National reimbursement dates of these drugs of these drugs in 29 European countries were obtained from national resources and from the pharmaceutical companies' affiliates. Result: As of February 2018, Crizotinib was reimbursed in 24/29 (83%) of countries. Ceritinib was reimbursed in 21/29 (72%) of countries while Alectinib was reimbursed in 12/29 (41%) countries. Pembrolizumab and Nivolumab were reimbursed for previously treated NSCLC in 21/29 (72%) and 18/29 (62%) countries respectively. Atezolizumab was reimbursed in 7/29 (24%) countries for previously treated NSCLC patients. Pembrolizumab for first line treatment of NSCLC was reimbursed in 20/29 (69%) countries, while in 9/29 (31%) (all Eastern European Countries) not reimbursed.
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